Comparison of Anesthetic Effects of Different Doses of Remimazolam Toislate Combined with Alfentanil in Painless Colonoscopy in Obese Patients

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200057652

Enrollment

Unknown

Registered

2022-03-15

Start date

2022-03-01

Completion date

Unknown

Last updated

2023-11-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Painless Colonoscopy

Interventions

R1:0.1mg/kg remimazolam toislate

R2: 0.2mg/kg remimazolam toislate

R3:0.25mg/kg remimazolam toislate

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. 18-65 years old; 2. BMI =28 kg/m2; 3. ASA Class I or II.

Exclusion criteria

Exclusion criteria: 1. Patients with allergy to remiazolam p-toluenesulfonate or alfentanil; 2. Decompensation of vital organs; 3. Serious systemic diseases, liver and kidney dysfunction; 4. Take psychotropic or analgesic drugs, severe OSASH (obstructive sleep apnea hypopnea syndrome).

Design outcomes

Primary

Measure	Time frame
Sedation success rate;	—

Secondary

Measure	Time frame
Mallampati grading;mouth opening degree;nail-chin distance;Mean arterial pressure;heart rate;oxygen saturation;remimazolam dosage;duration of examination;duration of anesthesia;time to wake up;time to leave hospital;patient satisfaction score and operator satisfaction score;	—

Countries

China

Contacts

Public ContactXu Hai

The Second Hospital of Jiaxing

xuhai@jxey.com+86 15988375602

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026